Loading…
To advance the care of patients at the intersection of liver disease and cancer through multidisciplinary collaboration, precision medicine, and evidence-based clinical decision-making.
Office bearers
Prof. Sanjaya Satapathy
Chair
MD · Liver Transplant
Why this SIG, right now
The overlap between liver disease and oncology is expanding rapidly, driven by advances in cancer therapeutics and the rising prevalence of chronic liver disease.
Three key forces define this moment:
Immune checkpoint inhibitors have transformed cancer care but introduced new challenges, including immune-mediated liver injury.
Many patients with cancer have:
Modern cancer therapies—including targeted agents and immunotherapies—are associated with:
Join Onco-Hepatology Special Interest Group to read and participate in the discussion board.
Sign In